| Regulatory status | PHASE 1 |
|---|---|
| Mechanism | Amylin analogue + dual GIP/GLP-1 (combination) |
| Developer | Eli Lilly |
| Form | Pre-mixed solution · 16mg, 32mg |
| CAS | Investigational (combination) |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
EloraTZP combines eloralintide, Lilly’s once-weekly amylin analogue, with tirzepatide, the dual GIP/GLP-1 agonist — three metabolic pathways in a single injection. In phase 1, adding eloralintide 3 mg to tirzepatide 5 mg produced 17% mean weight loss over 16 weeks, versus 10% with tirzepatide 5 mg alone. Phase 2 results are expected at EASD 2026. The earliest-stage compound on the site, listed for labs tracking the amylin-combination frontier. Each vial is formulated in-house to the exact 3:5 ratio of eloralintide to tirzepatide for precise measurement, and ships reconstituted — no reconstitution add-on needed.
This product ships reconstituted: refrigerate at 2–8°C on arrival and use promptly — no beyond-use date is validated. Keep away from light and heat.
Lilly's amylin-plus-tirzepatide combination. Three pathways, one injection.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
